Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Other solid neoplasm 2Gastrointestinal 1Classical hematology 1

Conditions

Solid Tumor 1Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × sotorasib × Other solid neoplasm × Clear all
NCT04380753 2026-05-06

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Amgen

Phase 1 Completed
12 enrolled 12 charts
Other solid neoplasm

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Allist Pharmaceuticals, Inc.

Phase 1/2 Completed
58 enrolled
Other solid neoplasmThoracic

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡